
    
      This is an observational, single institution study designed to determine the benefit of
      131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma,
      malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors. Response rate,
      time to progression, and quality of life changes will be evaluated.
    
  